Sanofi's Wayrilz Approved in Japan for ITP, Offering New Oral Treatment Option
SNY is trading near its 52-week low of $40.89 (1.9% above the low) on elevated volume (2.1× avg).
Summary
Sanofi's novel oral BTK inhibitor, Wayrilz (rilzabrutinib), has received marketing approval in Japan for the treatment of persistent or chronic immune thrombocytopenia (ITP). This approval is based on positive Phase 3 LUNA 3 study results, which demonstrated statistically significant improvements in platelet response and patient quality of life. This adds a new treatment option for patients who have not responded to existing therapies, addressing a significant unmet medical need. This approval continues a series of positive regulatory and clinical developments for Sanofi's pipeline in recent months.
At the time of this announcement, SNY was trading at $41.66 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $102.2B. The 52-week trading range was $40.89 to $52.68. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.